|
Treatment Options
|
Dipeptidyl Peptidase-4 Inhibitor
Sitagliptin is indicated as an adjunct to diet and exercise, as single therapy to improve glycemic control in persons with type 2 diabetes mellitus. It is also indicated to improve glycemic control, in combination with metformin or a thiazolidinedione (TZD), in persons with type 2 diabetes when the single agent alone, with diet and exercise, does not provide adequate glycemic control. Sitagliptin should be used carefully in people taking sulfonylureas due to an increased risk of hypoglycemia (low blood sugar).
Conversely, sitagliptin should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.
Drugs in the class
Sitagliptin tablets (Januvia) |
Note: The above information is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist, or other healthcare professional. It is not intended to diagnose a health condition, but it can be used as a guide to help you decide if you should seek professional treatment or to help you learn more about your condition once it has been diagnosed.
|
